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费增速 快的地区之一。2013 年，全国社会消费品零售总额为 23.44 万亿元，其
中药品流通销售额占比为 5.6%，同比提升 0.2%，金额达到 1.3 万亿元，同比 2012

























































Pharmaceutical industry is an important industry which is closely related tothe 
national economy and people's livelihood, as well asan important area for the nation 
to foster strategic emerging industries. The keydevelopment directionand main tasks 
of the State Council’s NO. (2012) 28th documentreleased on July 9th 2012,"Twelfth 
Five-Year "National Strategic Emerging Industry Development Plan,are the 
followingseven industries : energy saving and environmental industry、new generation 
of IT industry, bio-industry、high-end equipment manufacturing industry、 new energy 
industry、new materials industry、new energy vehicles industry, etc. As the most 
important components of bio-industry, Bio-pharmaceutical industry is included among 
the sevendevelopmentdirections.  
A set of datareleased by 2014 China Pharmaceutical Distribution Industry 
Capital Forum shows: China has become one of the fastest growing regions in drug 
consumption in the world. In 2013, China’s total retail sales of social consumer goods 
was 23.44 trillion Yuan, in which pharmaceutical distribution sales accounted for 
5.6%, increased by 0.2% on year, amounted to 1.3 trillion Yuan, an increase of 16.7% 
in 2012. And China is expected to be the world's second largest pharmaceutical 
market，only after the United States, before 2020. 
JointownPharmaceutical Group Co., Ltd. is an exotic flower as well as an 
unstainedlotus in China's pharmaceutical business market. Over the past 10 years,as a 
private enterprise,Jointown was lucky to survivefrom the dreadful environment of 
pharmaceutical and healthcare industry which is dominated bythe central enterprises、
state-owned enterprises. By struggling in only 15% share of the OTC drug 
market,Jointown achieved the fourth leading place in the industry. 
Jointownnever succumbs to the distorted market rules and the unspoken rules of 
the hospitals and doctors ， and completed the phoenix Pan-like 
transformationdoggedly relying on low-cost logistics strength, rapid expansion of the 
national sales and logistics network, as well as the unique pharmaceutical logistics 
planning and integration technology. The sales of Jointown has rapidly grown from 
small to large scale, which reached 33.4 billion Yuanrevenueexcluding tax in 2013. 
All the Jointownese and market peers say that the core competitiveness ofJointown 
growing from weak to strong, from small to large, is its logistics!  













become the main force in resources allocation , which brings the hope of new health 
care reformto Jointown; And new business model brings new markets, booming 
e-commerce, numerous mergers and acquisitions in medical and pension industry，
which makes Jointown deeply feels the new opportunities in new markets, as well as 
new challenges attendant. As Jointown’s survivalrecipe,Jointown pharmaceutical 
logistics needs to assess the situation and make careful analysisunder the joint effect 
of new markets、new policies, new challenges and new opportunities, as to the 
following questions：whether to do reorganization 、contraction or expansion and how 
to seize the opportunity to make up for their shortcomings, as well as how to enhance 
the strength to adapt to the rapidly changing market. 
Under the guidance of economic management theory of Enterprise Competitive 
Strategy Theory、Five Force Competitive Model, PEST Analysis Theory, this 
paperputs forward a strategic thinking ofJointown pharmaceutical logistics’next stage 
development, and the corresponding implementationsupporting measures by carrying 
out a detailed analysis of the macro environment through the development of 
pharmaceutical logistics、 industry competition landscape and competitive factors, as 
well as its own resource conditions.And in this paper, a macro direction to adhere to 
the road of overall cost leadership strategyin the competitive strategy is proposed to 
Jointown pharmaceutical logisticsbased on the good development prospects of the 
market and the enterprise’s practice， by theoretical analysis and empirical analysis 
method. 
This paper argues thatJointown logisticsshould not only servefor  consolidating 
the competitiveness of Jointown Group, but alsofor the entire pharmaceutical and 
health industry by utilizing the already established logistics network , and ultimately 
benefit the end- consumers relying on its low cost、nation-wide network 、rapid 
response，and establish a justice and fair market benchmark imagewhile doing good 
business，and at the same time make efforts to promote the healthy restructuring and 
sustainable development of the industry. 
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流通行业运行统计分析报告》，2013 年全国药品流通销售额达到 1.3 万亿，同比
增幅高达 16.7%。 
2013 年度全国共有药品批发企业 1.63 万家，中国药品流通行业销售排序前
10 名的企业名单，以年度销售总额排序见以下表 1-1 所示： 
 
表 1-1:中国药品流通行业销售额排名前十强① 
2013 年排名 公司名称 销售额 
1 中国医药集团总公司 1866 亿 
2 华润医药商业集团有限公司 735 亿 
3 上海医药集团股份有限公司 710 亿 
4 九州通医药集团有限公司 334 亿 
5 广州医药有限公司 246 亿 
6 重庆医药（集团）股份有限公司 210 亿 
7 南京医药股份有限公司 187 亿 
8 华东医药股份有限公司 167 亿 
9 四川科伦医药贸易有限公司 148 亿 
10 中国医药保健品股份有限公司 125 亿 
 
包括上述前 10 强在内的规模以上药品流通企业中，国有及国有控股企业主
营业务收入 6246 亿元，占药品流通企业主营业务总收入的 63.3%，实现利润 115
                                                             















亿元，占企业利润总额的 57.1%；股份制企业主营业务收入 2546 亿元，占主营
业务总收入的 25.8%，实现利润 59 亿元，占企业利润总额的 29.3%。此两项数字
说明，国有及国有控股企业、股份制企业占据了行业发展的主导地位。 
2013 年，全国六大区域销售总额比重分别为：华东 39.2%、中南 20.7%、华
北 18.7 %、西南 12.4%、东北 5.3%、西北 3.7%；其中华东、中南、华北三大区



















随着国家食品与药品监督管理总局于 2013 年颁布医药行业新版 GSP(GOOD 
SUPPLY PRACTICE 的缩写，称为药品经营质量管理规范)，2013 年以来各药品流通
企业“被迫”加大在物流建设上的投入，推动了现代医药物流和第三方物流业务
的发展。据国家医药商业协会统计预测，2014 年医药商业企业自有配送中心数
                                                             












































                                                             































表 1-2:2013 年以来跨界进入医药物流和冷链物流行业的典型案例 
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